Market Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says

MT Newswires Live

09/26

CSL (ASX:CSL) says it does not "expect any material impact" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.

The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.

The firm has a "very significant US manufacturing footprint," the spokesperson added.

It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2570079986"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570079986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570079986?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570079986","market":"hk","top_or_hot":-1,"title":"Market Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says","media":"MT Newswires Live","content":"<html><body><p> CSL (ASX:CSL) says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.</p><p>The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.</p><p>The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.</p><p>It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-26 14:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> CSL (ASX:CSL) says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.</p><p>The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.</p><p>The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.</p><p>It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡萊爾夥伴","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2570079986","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570079986","pubTimestamp":1758866697,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL  says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","BK7067":"生物科技","XJO.AU":"标普/澳交所 200指数","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7508":"医药生物股","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK7511":"ESG概念","BK7501":"新冠治疗股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","XKO.AU":"标普/澳交所 300指数","CSL.AU":"CSL LIMITED","XAO.AU":"标普/澳交所 普通股指数","BK4086":"建筑产品"},"translate_title":"市场热议：《澳大利亚人报》表示，CSL“预计美国药品关税不会产生任何重大影响”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XAO.AU":1.5,"CSL":1.5,"XJO.AU":1.5,"XKO.AU":1.5,"CSL.AU":1.5},"content_text":"CSL (ASX:CSL) says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}